March 2025
BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
Staff, Partner in relationship, CAB, BioAtla, 30%
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy
Merck’s Injectable Keytruda Shows Promising Results in Pivotal Trial
Keytruda, subcutaneous injection, intravenous formula, non-small cell lung cancer, pivotal trial, Merck
Equillium’s pivotal GvHD study of anti-CD6 antibody comes up short
United States Food and Drug Administration, itolizumab, In complete remission, day, Equillium
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date
HHS Overhaul: RFK Jr. Cuts 20,000 Jobs in Major Restructuring
Robert F. Kennedy Jr., Department of Health and Human Services (HHS), job cuts, restructuring, Administration for a Healthy America (AHA), chronic disease epidemic, efficiency, cost-saving
Galatea Bio’s $25M Funding Boost for Global Biobank and AI-Driven Genomic Research
Galatea Bio, global biobank, AI-enabled genomic analysis, precision medicine, non-European ancestry, genetic diversity
Chiesi unveils 430M investment to revitalize Italian production site for inhaler, biologics manufacturing
Investments, Inhaler, Biological Factors, production
Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program
Nkarta, restructuring, Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019, Cell Therapy